Gene-Edited Allogeneic Cell Therapies

Allogeneic cell therapies can enable “off-the-shelf” treatment options. Conventional allogeneic cell therapy approaches can result in rejection, low potency, and in the case of allogeneic immune cell therapy, graft-versus-host disease.

Our scientists developed a technology that uses gene editing to address limitations of conventional approaches to allogeneic cell therapy⁵. This technology can be used to generate allogeneic cell therapies with high potency and enhanced targeting.

The Gene-Edited Allogeneic Cell Therapies technology is protected by a pending U.S. patent (with additional patents pending in other countries).

• Ultra-high efficiency editing of T cells, fibroblasts, keratinocytes, and pluripotent stem cells
• Ultra-high specificity gene editing
• Virus-free and DNA-free gene editing
• Gene repair using a DNA-repair template

• Donor sequence insertion into a target genomic locus (e.g., TRAC, AAVS1 safe harbor, etc.)
• Gene-editing therapies (ex vivo and in vivo)
• Allogeneic engineered cell therapies (e.g., CAR-T, CAR-NK, stem cell-derived therapies, etc.)